ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.08B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.89M
Average 1.66M
ACAD Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
ACADIA Pharmaceuticals Inc.NASDAQ: ACAD
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development declines year over year
Q3 FY2026 research & development of $76.28M fell 13.1% year over year, behind the -7.3% change in trailing-twelve-month research & development. Sequentially, it fell 6.5% from the prior quarter. Over 3 fiscal years it compounded at -3.1% a year.
Context
- Research & development amounted to 30.7% of revenue in FY2025, down 1.0 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -13.1% toward the trailing-twelve-month pace of -7.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 328.8M USD
- Year-over-year change
- +8.4%
- 4-year CAGR
- +8.3%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 328.8M | +8.4% |
| FY2024 | 2024-12-31 | 303.25M | -13.8% |
| FY2023 | 2023-12-31 | 351.62M | -2.8% |
| FY2022 | 2022-12-31 | 361.58M | +51.0% |
| FY2021 | 2021-12-31 | 239.42M | — |
Research & Development vs competitors
How ACAD compares with its peers on the latest reported figures
- ACAD's LTM Sep 2026 research & development of $319.46M is the highest of the 11 companies compared; the peer median is $104.96M.
- Its year-over-year change of -7.3% is the 8th highest of 10, against a peer median of +14.6%.
- Research & development amounts to 26.6% of revenue for ACAD, versus a peer median of 46.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $319.46M | -7.3% | -3.1% | 26.6% | |
| LTM Sep 2026 | $289.11M | +17.6% | +19.9% | — | |
| LTM Jun 2026 | $187.86M | -3.5% | +46.8% | 24.2% | |
| LTM Mar 2026 | $171.97M | +136.8% | +73.1% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $162.51M | -21.6% | +18.9% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.93M | +58.7% | +118.3% | 539.7% |
| LTM Mar 2026 | $101.99M | +14.6% | +8.4% | 46.8% | |
| LTM Mar 2026 | $55.94M | +19.0% | +24.4% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M | +11.3% | +45.0% | — |
| LTM Dec 2025 | $31.8M | -27.0% | -0.3% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $28.47M | — | +131.7% | — |
| Peer median (excluding ACAD) | $104.96M | +14.6% | +34.7% | 46.8% | |
Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 484.15M | 517.24M | 726.44M | 957.8M | 1.07B |
| Cost of Revenue | 19.14M | 10.17M | 45.73M | 81.84M | 89M |
| Gross Profit | 465M | 507.07M | 680.71M | 875.96M | 982.51M |
| Gross Margin | 96.0% | 98.0% | 93.7% | 91.5% | 91.7% |
| Research & Development | 239.42M | 361.58M | 351.62M | 303.25M | 328.8M |
| Selling, General & Admin | 396.03M | 369.09M | 402.47M | 488.43M | 548.89M |
| Operating Expenses | 635.44M | 730.67M | 754.09M | 645.16M | 877.7M |
| Depreciation & Amortization | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| EBITDA | (164.18M) | (211.42M) | (45.48M) | 100.16M | 150.66M |
| EBITDA Margin | -33.9% | -40.9% | -6.3% | 10.5% | 14.1% |
| Operating Income | (170.44M) | (223.6M) | (73.38M) | 230.79M | 104.81M |
| Operating Margin | -35.2% | -43.2% | -10.1% | 24.1% | 9.8% |
| Interest Income | 591K | 6.61M | 17.23M | 25.46M | 31.72M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.92M | 10.15M | 22.34M | 27.28M | 34.09M |
| Income Before Tax | (167.52M) | (213.44M) | (51.04M) | 258.08M | 138.9M |
| Pre-Tax Margin | -34.6% | -41.3% | -7.0% | 26.9% | 13.0% |
| Income Tax Expense | 351K | 2.53M | 10.25M | 31.62M | (252.1M) |
| Net Income | (167.87M) | (215.98M) | (61.29M) | 226.45M | 391M |
| Net Margin | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% |
| EPS (Basic) | (1.05) | (1.34) | (0.37) | 1.37 | 2.32 |
| EPS (Diluted) | (1.05) | (1.34) | (0.37) | 1.36 | 2.29 |
| Weighted Avg Shares | 160.49M | 161.68M | 163.82M | 165.72M | 169.34M |
| Weighted Avg Shares (Diluted) | 160.49M | 161.68M | 163.82M | 166.36M | 171.36M |
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.